MicroRNA‑1915‑3p prevents the apoptosis of lung cancer cells by downregulating DRG2 and PBX2

Xu,Chengshan; Li,Hengheng; Zhang,Ling; Jia,Tianjun; Duan,Lianning; Lu,Chengrong

doi:10.3892/mmr.2015.4565

MicroRNA‑1915‑3p prevents the apoptosis of lung cancer cells by downregulating DRG2 and PBX2

Authors:
- Chengshan Xu
- Hengheng Li
- Ling Zhang
- Tianjun Jia
- Lianning Duan
- Chengrong Lu
View Affiliations

Affiliations: Aviation Medicine Research Laboratory, Air Force General Hospital, PLA, Beijing 100142, P.R. China, Graduate Student Ministry of Education, Hebei North University, Zhangjiakou, Hebei 075000, P.R. China, College of Medical Laboratory, Hebei North University, Zhangjiakou, Hebei 075000, P.R. China
Published online on: November 13, 2015 https://doi.org/10.3892/mmr.2015.4565
Pages: 505-512

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Micro (mi)RNAs are short non‑coding RNA molecules, which post‑transcriptionally regulate gene expression and exert key roles in cell growth, differentiation and apoptosis. In the present study, the mechanism and the function of miR‑1915‑3p in the apoptotic regulation of lung cancer cell lines (NCI‑H441 and NCI‑H1650) were investigated. The expression analysis confirmed that the expression of miR‑1915‑3p was markedly decreased in the apoptotic cells. The overexpression of miR‑1915‑3p in the lung cancer cells prevented apoptosis induced by etoposide. Developmentally regulated GTP‑binding protein 2 (DRG2) and pre‑B cell leukemia homeobox 2 (PBX2) were identified as downstream targets of miR‑1915‑3p, which was shown to bind directly to the 3'‑untranslated region of DRG2 and PBX2, subsequently lowering their mRNA and protein expression levels. Co‑expression of miR‑1915‑3p and DRG2/PBX2 in the NCI‑H441 and NCI‑H1650 cells partly circumvented the effect of miR‑1915‑3p on apoptosis. The results in the present study revealed that miR‑1915‑3p functions as a silencer of apoptosis, which regulates lung cancer apoptosis via targeting DRG2/PBX2, and consequently this miRNA may be a putative therapeutic target in lung cancer.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
3	Spiro SG and Silvestri GA: One hundred years of lung cancer. Am J Resp Crit Care Med. 17:2523–2529. 2005.
4	Harmsma M, Schutte B and Ramaekers FC: Serum markers in small cell lung cancer: Opportunities for improvement. Biochim Biophys Acta. 1836:255–272. 2013.PubMed/NCBI
5	Fernandez S, Risolino M, Mandia N, Talotta F, Soini Y, Incoronato M, Condorelli G, Banfi S and Verde P: miR-340 inhibits tumor cell proliferation and induces apoptosis by targeting multiple negative regulators of p27 in non-small cell lung cancer. Oncogene. 34:3240–3250. 2014. View Article : Google Scholar : PubMed/NCBI
6	Hu J, Cheng Y, Li Y, Jin Z, Pan Y, Liu G, Fu S, Zhang Y, Feng K and Feng Y: microRNA-128 plays a critical role in human non-small cell lung cancer tumourigenesis, angiogenesis and lymphangiogenesis by directly targeting vascular endothelial growth factor-C. Eur J Cancer. 50:2336–2350. 2014. View Article : Google Scholar : PubMed/NCBI
7	Fiori ME, Barbini C, Haas TL, Marroncelli N, Patrizii M, Biffoni M and De Maria R: Antitumor effect of miR-197 targeting in p53 wild-type lung cancer. Cell Death Differ. 21:774–782. 2014. View Article : Google Scholar : PubMed/NCBI
8	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
9	Harfe BD: MicroRNAs in vertebrate development. Curr Opin Genet Dev. 15:410–415. 2005. View Article : Google Scholar : PubMed/NCBI
10	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
11	He HC, Han ZD, Dai QS, Ling XH, Fu X, Lin ZY, Deng YH, Qin GQ, Cai C, Chen JH, et al: Global analysis of the differentially expressed miRNAs of prostate cancer in Chinese patients. BMC Genomics. 14:7572013. View Article : Google Scholar : PubMed/NCBI
12	White NM, Khella HW, Grigull J, Adzovic S, Youssef YM, Honey RJ, Stewart R, Pace KT, Bjarnason GA, Jewett MA, et al: miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215. Br J Cancer. 105:1741–1749. 2011. View Article : Google Scholar : PubMed/NCBI
13	Chen L, Li Y, Fu Y, Peng J, Mo MH, Stamatakos M, Teal CB, Brem RF, Stojadinovic A, Grinkemeyer M, et al: Role of deregulated microRNAs in breast cancer progression using FFPE tissue. PLoS One. 8:e542132013. View Article : Google Scholar : PubMed/NCBI
14	Sallustio F, Serino G, Costantino V, Curci C, Cox SN, De Palma G and Schena FP: miR-1915 and miR-1225-5p regulate the expression of CD133, PAX2 and TLR2 in adult renal progenitor cells. PLoS One. 8:e682962013. View Article : Google Scholar : PubMed/NCBI
15	Nakazawa K, Dashzeveg N and Yoshida K: Tumor suppressor p53 induces miR-1915 processing to inhibit Bcl-2 in the apoptotic response to DNA damage. FEBS J. 281:2937–2944. 2014. View Article : Google Scholar : PubMed/NCBI
16	Xu K, Liang X, Cui D, Wu Y, Shi W and Liu J: miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells. Mol Carcinog. 52:70–78. 2013. View Article : Google Scholar
17	Yekta S, Shih IH and Bartel DP: MicroRNA-directed cleavage of HOXB8 mRNA. Science. 304:594–596. 2004. View Article : Google Scholar : PubMed/NCBI
18	Dong Y, Xiong M, Duan L, Liu Z, Niu T, Luo Y, Wu X, Xu C and Lu C: H2AX phosphorylation regulated by p38 is involved in Bim expression and apoptosis in chronic myelogenous leukemia cells induced by imatinib. Apoptosis. 19:1281–1292. 2014. View Article : Google Scholar : PubMed/NCBI
19	Pommier Y, Leo E, Zhang H and Marchand C: DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 17:421–433. 2010. View Article : Google Scholar : PubMed/NCBI
20	Cui X, Choi HK, Choi YS, Park SY, Sung GJ, Lee YH, Lee J, Jun WJ, Kim K, Choi KC, et al: DNAJB1 destabilizes PDCD5 to suppress p53-mediated apoptosis. Cancer Lett. 357:307–315. 2015. View Article : Google Scholar
21	Park JH, Lee SW, Yang SW, Yoo HM, Park JM, Seong MW, Ka SH, Oh KH, Jeon YJ and Chung CH: Modification of DBC1 by SUMO2/3 is crucial for p53-mediated apoptosis in response to DNA damage. Nat Commun. 5:54832014. View Article : Google Scholar : PubMed/NCBI
22	Okamoto S, Jiang Y, Kawamura K, Shingyoji M, Tada Y, Sekine I, Takiguchi Y, Tatsumi K, Kobayashi H, Shimada H, et al: Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions. Cell Death Dis. 5:e15172014. View Article : Google Scholar : PubMed/NCBI
23	Liu J, Uematsu H, Tsuchida N and Ikeda MA: Essential role of caspase-8 in p53/p73-dependent apoptosis induced by etoposide in head and neck carcinoma cells. Mol Cancer. 10:952011. View Article : Google Scholar : PubMed/NCBI
24	Hande KR: Etoposide: Four decades of development of a topoisomerase II inhibitor. Eur J Cancer. 34:1514–1521. 1998. View Article : Google Scholar
25	Zhang Y, Geng L, Talmon G and Wang J: MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer. J Biol Chem. 290:6215–6225. 2015. View Article : Google Scholar : PubMed/NCBI
26	Adi Harel S, Bossel Ben-Moshe N, Aylon Y, Bublik DR, Moskovits N, Toperoff G, Azaiza D, Biagoni F, Fuchs G, Wilder S, et al: Reactivation of epigenetically silenced miR-512 and miR-373 sensitizes lung cancer cells to cisplatin and restricts tumor growth. Cell Death Differ. 22:1328–1340. 2015. View Article : Google Scholar : PubMed/NCBI
27	Yang CH, Pfeffer SR, Sims M, Yue J, Wang Y, Linga VG, Paulus E, Davidoff AM and Pfeffer LM: The oncogenic microRNA-21 inhibits the tumor suppressive activity of FBXO11 to promote tumorigenesis. J Biol Chem. 290:6037–6046. 2015. View Article : Google Scholar : PubMed/NCBI
28	Chen J, Shen BY, Deng XX, Zhan Q and Peng CH: SKP1-CULLIN1-F-box (SCF)-mediated DRG2 degradation facilitated chemotherapeutic drugs induced apoptosis in hepatocellular carcinoma cells. Biochem Biophys Res Commun. 420:651–655. 2012. View Article : Google Scholar : PubMed/NCBI
29	Song H, Kim SI, Ko MS, Kim HJ, Heo JC, Lee HJ, Lee HS, Han IS, Kwack K and Park JW: Overexpression of DRG2 increases G2/M phase cells and decreases sensitivity to nocodazole-induced apoptosis. J Biochem. 135:331–335. 2004. View Article : Google Scholar : PubMed/NCBI
30	Ko MS, Lee UH, Kim SI, Kim HJ, Park JJ, Cha SJ, Kim SB, Song H, Chung DK, Han IS, et al: Overexpression of DRG2 suppresses the growth of Jurkat T cells but does not induce apoptosis. Arch Biochem Biophys. 422:137–144. 2004. View Article : Google Scholar : PubMed/NCBI
31	Qiu Y, Song B, Zhao G, Deng B, Makino T, Tomita Y, Wang J, Luo W, Doki Y, Aozasa K, et al: Expression level of Pre B cell leukemia homeobox 2 correlates with poor prognosis of gastric adenocarcinoma and esophageal squamous cell carcinoma. Int J Oncol. 36:651–663. 2010.PubMed/NCBI